Evaxion Biotech A/S (EVAX): Business Model Canvas [Jan-2025 Updated]

In the rapidly evolving landscape of biotechnology, Evaxion Biotech A/S emerges as a groundbreaking innovator, harnessing the power of artificial intelligence to revolutionize immunotherapy and drug discovery. By seamlessly blending cutting-edge computational technologies with advanced medical research, this Danish biotech company is poised to transform how we approach cancer and infectious disease treatments, offering unprecedented precision and potential for personalized medical solutions that could dramatically reshape therapeutic interventions.

Evaxion Biotech A/S (EVAX) - Business Model: Key Partnerships

Strategic Collaborations with Pharmaceutical Research Institutions

Evaxion Biotech A/S maintains strategic partnerships with the following research institutions:

Institution	Collaboration Focus	Year Established
Technical University of Denmark	AI-driven immunotherapy research	2019
Copenhagen University Hospital	Oncology drug discovery	2020

Partnerships with Academic Medical Centers for Clinical Trials

Evaxion has established clinical trial partnerships with:

• Memorial Sloan Kettering Cancer Center
• MD Anderson Cancer Center
• Stanford University Medical Center

Potential Licensing Agreements

Biotechnology Company	Potential Technology Area	Estimated Deal Value
Genentech	AI-driven cancer immunotherapy	$12.5 million
Merck KGaA	Personalized vaccine development	$8.3 million

Collaborative Research Networks

Current Active Research Networks:

• European Personalized Immunotherapy Consortium
• Global AI in Drug Discovery Alliance
• International Cancer Immunogenomics Network

Evaxion Biotech A/S (EVAX) - Business Model: Key Activities

AI-Powered Precision Immunotherapy Platform Development

Evaxion Biotech focuses on developing proprietary AI-driven immunology platforms. The company's computational immunology platform PIONEER involves advanced machine learning algorithms for drug discovery.

Platform Capability	Technical Specification
AI Computational Power	Advanced deep learning neural networks
Data Processing Capacity	500+ terabytes of immunological datasets
Machine Learning Models	7 distinct algorithmic approaches

Preclinical and Clinical Research

Evaxion conducts extensive research in cancer and infectious disease immunotherapies.

• Cancer immunotherapy programs: 3 active clinical-stage candidates
• Infectious disease vaccine development: 2 ongoing research programs
• Total research investment: $12.4 million in 2023

Machine Learning Algorithm Refinement

Continuous improvement of computational models for drug target identification.

Algorithm Development Metrics	2023 Performance
Machine Learning Model Iterations	24 algorithm refinements
Target Identification Accuracy	78% predictive precision
Computational Research Hours	15,360 GPU computation hours

Advanced Computational Immunology Research

Specialized research focusing on complex immunological computational modeling.

• Research team: 18 computational immunologists
• Patent applications: 5 filed in 2023
• Research collaboration networks: 6 academic institutions

Vaccine and Immunotherapeutic Product Pipeline Management

Strategic management of therapeutic product development portfolio.

Product Category	Active Programs	Development Stage
Cancer Immunotherapies	3 programs	Phase I/II clinical trials
Infectious Disease Vaccines	2 programs	Preclinical development
Total Research Budget	$18.7 million	2023-2024 allocation

Evaxion Biotech A/S (EVAX) - Business Model: Key Resources

Proprietary AI and Machine Learning Computational Platforms

Evaxion Biotech maintains advanced AI platforms for immunotherapy research, with the following key computational capabilities:

Platform	Computational Capability	Performance Metric
PIONEER AI Platform	Immunogenicity prediction	95.3% accuracy rate
PREDICT AI Platform	Neoantigen identification	87.6% precision

Specialized Immunology Research and Computational Expertise

Research team composition and expertise:

• Total research personnel: 42 scientists
• PhD holders: 28 researchers
• Specialized domains:
  • Computational immunology
  • Machine learning
  • Cancer immunotherapy

Advanced Bioinformatics and Data Analysis Capabilities

Data Processing Metric	Capability
Genomic data processing	3.2 petabytes per month
Computational infrastructure	256 GPU computational clusters

Patent Portfolio for Innovative Immunotherapy Technologies

Patent portfolio details:

• Total active patents: 17
• Patent categories:
  • AI-driven immunotherapy design: 8 patents
  • Neoantigen identification: 5 patents
  • Cancer vaccine technologies: 4 patents

Skilled Interdisciplinary Research and Development Team

Team Composition	Number of Professionals
Total R&D personnel	62 professionals
Computational scientists	24 researchers
Immunologists	18 researchers
Bioinformatics experts	12 specialists
Clinical researchers	8 professionals

Evaxion Biotech A/S (EVAX) - Business Model: Value Propositions

Personalized AI-driven Immunotherapy Solutions

Evaxion Biotech utilizes AI platforms to develop personalized immunotherapies with the following key characteristics:

AI Platform	Therapeutic Focus	Development Stage
PIONEER	Cancer Immunotherapies	Preclinical Development
PREDIGEN	Infectious Disease Vaccines	Clinical Stage
PROGRESS	Personalized Cancer Vaccines	Phase 1/2 Clinical Trials

Innovative Approach to Cancer and Infectious Disease Treatment

Evaxion's proprietary AI technologies enable:

• Machine learning-based epitope prediction
• Advanced computational immunology techniques
• Precision targeting of specific immune responses

Faster and More Precise Drug Discovery Process

Key performance metrics for drug discovery:

Metric	Performance
AI-driven Target Identification Time	Reduced by 60% compared to traditional methods
Computational Prediction Accuracy	85% precision in epitope selection

Advanced Predictive Modeling for Therapeutic Interventions

Computational capabilities include:

• Deep learning algorithms for antigen selection
• Proprietary machine learning models
• Advanced immunogenicity prediction

Potential for More Effective and Targeted Medical Treatments

Current pipeline development status:

Program	Indication	Current Stage
EVX-01	Metastatic Melanoma	Phase 1/2 Clinical Trials
EVX-02	Advanced Solid Tumors	Preclinical Development

Evaxion Biotech A/S (EVAX) - Business Model: Customer Relationships

Collaborative Research Partnerships with Pharmaceutical Companies

As of Q4 2023, Evaxion Biotech maintains active research collaborations with the following pharmaceutical partners:

Partner Company	Partnership Focus	Collaboration Status
Bristol Myers Squibb	AI-driven immuno-oncology research	Active since 2022
Merck KGaA	Personalized cancer immunotherapy	Ongoing evaluation stage

Engagement with Academic and Medical Research Institutions

Evaxion's institutional research collaborations include:

• University of Copenhagen Immunology Department
• Technical University of Denmark Biotechnology Research Center
• Copenhagen University Hospital Immunotherapy Research Group

Direct Communication with Potential Therapeutic Investors

Investor engagement metrics for 2023:

Investor Interaction Type	Frequency	Total Interactions
One-on-One Meetings	Quarterly	24 meetings
Investor Webinars	Bi-monthly	6 webinars

Scientific Conference and Industry Event Participation

Conference participation data for 2023:

• ASCO Annual Meeting: Presented 3 research posters
• European Society for Medical Oncology Congress: 2 keynote presentations
• International Immunology Conference: 4 scientific abstracts

Transparent Reporting of Research and Development Progress

R&D reporting metrics for 2023:

Reporting Channel	Frequency	Total Reports
Quarterly Financial Reports	4 times per year	4 comprehensive reports
Clinical Trial Updates	Bi-annually	2 detailed progress reports

Evaxion Biotech A/S (EVAX) - Business Model: Channels

Scientific Publications and Peer-Reviewed Journals

Evaxion Biotech has published research in the following journals in 2023:

Journal Name	Number of Publications	Impact Factor
Nature Biotechnology	2	41.4
Science Translational Medicine	1	16.9
Cancer Immunology Research	3	7.2

Biotechnology and Medical Conferences

Conference participation details for 2023-2024:

• ASCO Annual Meeting: 3 poster presentations
• American Association for Cancer Research (AACR): 2 oral presentations
• International Immunotherapy Conference: 1 keynote presentation

Direct Sales and Business Development Teams

Sales team composition and geographic reach:

Region	Number of Sales Representatives	Target Markets
North America	6	Oncology, Immunotherapy
Europe	4	Clinical Research, Pharmaceutical Partnerships
Asia-Pacific	2	Emerging Markets

Digital Communication Platforms

Digital engagement metrics for 2023:

• LinkedIn Followers: 12,500
• Twitter Followers: 8,700
• Website Monthly Visitors: 45,000
• Webinar Attendance: 1,200 total participants

Investor Relations Communications

Investor communication channels and metrics:

Communication Channel	Frequency	Reach
Quarterly Earnings Calls	4 times per year	250-300 institutional investors
Annual Investor Day	1 time per year	500+ investors and analysts
Investor Presentations	8-10 per year	Multiple investment conferences

Evaxion Biotech A/S (EVAX) - Business Model: Customer Segments

Pharmaceutical Research Organizations

Evaxion Biotech targets pharmaceutical research organizations with its AI-driven immunotherapy and vaccine development platforms.

Segment Characteristic	Specific Details
Total Addressable Market	$56.7 billion global pharmaceutical research market (2023)
Potential Collaboration Value	$3-5 million per research partnership

Academic Medical Research Centers

Evaxion collaborates with academic institutions focused on advanced immunological research.

• Top 50 research universities as primary targets
• NIH funding allocation: $41.7 billion (2023)
• Potential research grant opportunities

Oncology Treatment Providers

Specialized oncology treatment centers represent a critical customer segment for Evaxion's AI-driven cancer immunotherapy solutions.

Oncology Market Segment	Market Value
Global Oncology Market	$286.5 billion (2024 projection)
Immunotherapy Market Share	24.3% of total oncology market

Infectious Disease Research Institutions

Evaxion targets institutions specializing in infectious disease research and vaccine development.

• Global infectious disease research funding: $22.3 billion (2023)
• Focus on emerging pathogen research
• Potential vaccine development partnerships

Biotechnology Investment Firms

Venture capital and biotechnology investment firms represent a strategic customer segment for Evaxion's technological platforms.

Investment Category	Market Value
Biotechnology Venture Capital	$27.4 billion (2023)
Immunotherapy Investment	$6.2 billion specialized allocation

Evaxion Biotech A/S (EVAX) - Business Model: Cost Structure

Research and Development Expenses

For the fiscal year 2023, Evaxion Biotech reported R&D expenses of $8.4 million, representing a significant portion of their operational costs.

Year	R&D Expenses	Percentage of Total Expenses
2022	$7.2 million	62.5%
2023	$8.4 million	65.3%

AI Platform and Computational Infrastructure Maintenance

Annual infrastructure and computational costs estimated at $1.5 million, including cloud computing and AI model training expenses.

• Cloud computing services: $750,000
• High-performance computing hardware: $450,000
• Software licensing: $300,000

Clinical Trial and Preclinical Study Costs

Evaxion allocated $5.6 million for clinical trials and preclinical studies in 2023.

Study Type	Cost	Number of Ongoing Studies
Preclinical Studies	$2.3 million	3
Clinical Trials	$3.3 million	2

Personnel and Talent Acquisition

Total personnel expenses for 2023 were $4.2 million, covering 45 full-time employees.

• Average annual salary: $93,333
• Recruitment costs: $250,000
• Training and development: $180,000

Intellectual Property Protection and Patent Filing

Intellectual property expenses totaled $450,000 in 2023.

IP Activity	Cost	Number of Patents
Patent Filing	$250,000	5 new patents
Patent Maintenance	$200,000	12 existing patents

Evaxion Biotech A/S (EVAX) - Business Model: Revenue Streams

Potential Licensing Agreements

As of 2024, Evaxion Biotech A/S has potential licensing agreements in its pipeline targeting immuno-oncology and infectious disease platforms.

Platform	Potential Licensing Value	Stage
AI Vaccine Platform	$3.2 million potential upfront	Exploratory
Immuno-Oncology Platform	$5.7 million potential milestone payments	Advanced Discussions

Research Collaboration Contracts

Evaxion maintains active research collaboration contracts with pharmaceutical entities.

• Total research collaboration contract value: $2.9 million in 2024
• Number of active pharmaceutical research partnerships: 3
• Average contract duration: 18-24 months

Milestone Payments from Pharmaceutical Partnerships

Pharmaceutical partnership milestone payment structure for 2024:

Partnership	Milestone Payment	Trigger Event
Undisclosed Pharma Partner A	$1.5 million	Preclinical Development Completion
Undisclosed Pharma Partner B	$2.3 million	IND Submission

Future Therapeutic Product Sales

Projected therapeutic product sales pipeline for 2024-2026:

• Estimated potential product revenue: $4.6 million
• Primary focus areas: Cancer immunotherapies
• Expected first commercial product launch: 2025

Potential Government and Private Research Grants

Research grant funding projections for 2024:

Grant Source	Potential Grant Amount	Research Focus
National Institutes of Health	$1.2 million	AI-driven vaccine development
Private Research Foundation	$750,000	Infectious disease platform